|Day Low/High||85.96 / 90.29|
|52 Wk Low/High||77.50 / 125.86|
SAN FRANCISCO, Nov. 9, 2018 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc.
- New MappingHepC.com website provides HCV community an easily accessible source of chronic HCV epidemiology data
NEW YORK, Nov. 7, 2018 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AbbVie Inc.
The gloom is so thick you can cut it with a knife.
SHAK beat expectations for both EPS and revenue, but same-store sales decreased. Here is how I would play it.
- Reports Third-Quarter Diluted EPS of $1.81 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 51.8 Percent
Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
- The approval is based on the MURANO Phase 3 clinical trial, in which VENCLYXTO® plus rituximab reduced the risk of disease progression or death by 83 percent and overall survival was prolonged compared to bendamustine in combination with rituximab, a standard of care chemoimmunotherapy regimen¹
- Randomized Phase 3 trial met primary endpoint, demonstrating patients treated with venetoclax plus obinutuzumab had superior progression-free survival (PFS) compared to patients treated with standard of care obinutuzumab plus chlorambucil
There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.
The most recent short interest data has been released for the 10/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim Cramer takes a closer look at Clorox, Sirius XM Radio, New Relic, AbbVie, ShotSpotter and more.
Jim Cramer asks if the Fed is trying so hard to cool the economy that it could crush wage growth.
Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.
Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.
Jim Cramer takes a look at AbbVie, Greendot, Sherwin-Williams, Visteon, TransEnterix, Duke Energy, Buckeye Partners, Arch Coal and more.
Jim Cramer says that in good markets there are always multiple ways for investors to win.
NORTH CHICAGO, Ill., Oct.
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in AbbVie, Inc.
- Upadacitinib monotherapy showed improvements in physical function, a measure that assesses patients' ability to perform daily activities and level of disability, versus methotrexate at week 14
- In U-ACHIEVE, upadacitinib (15/30/45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints, including endoscopic improvement, clinical remission (per Full Mayo Score) and clinical response, in patients with moderately to severely active ulcerative colitis
- Agreements Provide Non-Exclusive License to Fresenius Kabi for HUMIRA-Related Intellectual Property in the U.S. Effective September 30, 2023, and in Other Markets on Different Dates
Collaboration leverages Morphic's unique platform for developing oral integrin drugs and AbbVie's global development and commercialization capabilities
- If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment
Law Offices of Howard G. Smith reminds investors of the October 22, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased AbbVie Inc.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.